Please ensure Javascript is enabled for purposes of website accessibility

Why Amarin Stock Imploded in March

By George Budwell – Apr 6, 2020 at 10:18AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Amarin's sole revenue generator was stripped of its patent protection in the U.S. last month.

What happened

Amarin (AMRN -1.65%) lost a staggering 72.7% of its value in March, according to data from S&P Global Market Intelligence. The drugmaker's shares collapsed late in the month following an adverse patent ruling for its prescription omega-3 treatment, Vascepa. 

This somewhat surprising patent decision by the U.S. District Court for the District of Nevada paves the way for generics to enter the all-important U.S. market. The company said it will file an immediate injunction to block the launch of a generic upon approval. Amarin also plans on appealing the decision. 

A downward trending red arrow set against a black background.

Image source: Getty Images.

So what

If generics do enter the U.S. market, Vascepa's sales may take a big hit. How big of a hit isn't entirely clear, because the drug is already reasonably priced -- meaning that generic manufacturers probably won't be able to sharply undercut Vascepa on price. But the more important issue is that Amarin won't be able to take advantage of regular price increases in the U.S. to boost sales. Without that added revenue, Vascepa is unlikely to ever achieve megablockbuster sales -- that is, annual sales exceeding $5 billion per year. 

Now what

There are some reasons for Amarin's shareholders to be optimistic, however. There is a chance this patent decision could be overturned upon appeal. What's more, there are no generics set to launch in the U.S. anytime soon, and Vascepa's international IP is unaffected by this ruling. So, in all, Amarin should still be able to generate upwards of at least $1 billion in annual sales by this time next year. Therefore, this small-cap biotech stock might be grossly undervalued after this sharp decline in March. 

George Budwell owns shares of Amarin. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amarin Stock Quote
$1.19 (-1.65%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.